Pure Bioscience - Current report filing (8-K)
March 31 2008 - 8:25AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 31, 2008
Date of Report (Date of earliest event reported):
PURE
BIOSCIENCE
(Exact name of registrant as specified in charter)
|
|
|
California
(State or other jurisdiction of incorporation)
|
|
33-0530289
(IRS Employer Identification No.)
|
1725 Gillespie
Way, El Cajon, California 92020
(Address of principal executive offices)
(619) 586
8600
Registrant’s telephone number, including area code:
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01.
Regulation FD Disclosure
Item 8.01. Other Events.
On March 31, 2008, PURE Bioscience
announced today that its application for listing of its common stock has been approved by
The NASDAQ Stock Market. PURE Bioscience anticipates that its common stock will begin
trading on The NASDAQ Capital Market at the opening of the market on Wednesday April 2,
2008. The stock will trade under the symbol PURE. The Press Release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this 8-K
(including Exhibit 99.1) is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the
date of this report, except as shall be expressly set forth by specific reference in such
filing.
This Current Report on Form 8-K
contains forward-looking statements that do not convey historical information,
but relate to predicted or potential future events, such as statements of our plans,
strategies and intentions. These statements can often be identified by the use of
forward-looking terminology such as believe, expect,
intend, may, will, should, or
anticipate or similar terminology. All statements other than statements of
historical facts included in this Current Report on Form 8-K are forward-looking
statements. All forward-looking statements speak only as of the date of this Current
Report on Form 8-K. Except for PUREs ongoing obligations to disclose material
information under the federal securities laws, PURE undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new information, future
events or otherwise. In addition to the risks and uncertainties of ordinary business
operations and conditions in the general economy and the markets in which Pure competes,
the forward-looking statements of PURE contained in this Current Report on Form 8-K are
also subject various risks and uncertainties, including those set forth in Risk
Factors, in PUREs Annual Report on Form 10-KSB for the fiscal year ended JULY
31, 2007, and in its subsequent filings made with the Securities and Exchange Commission.
Item 9.01. Financial
Statements and Exhibits
(d)
|
The
following exhibits are filed with this report:
|
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release dated March 31, 2008
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
PURE BIOSCIENCE
Dated: March 31, 2008
/s/ Michael L. Krall
Michael L. Krall, Chief
Executive Officer
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jul 2023 to Jul 2024